Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1997 Oct;41(10):2076–2082. doi: 10.1128/aac.41.10.2076

In vivo antiviral activity and pharmacokinetics of (-)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine in woodchuck hepatitis virus-infected woodchucks.

J M Cullen 1, S L Smith 1, M G Davis 1, S E Dunn 1, C Botteron 1, A Cecchi 1, D Linsey 1, D Linzey 1, L Frick 1, M T Paff 1, A Goulding 1, K Biron 1
PMCID: PMC164073  PMID: 9333028

Abstract

The (-) enantiomer of cis-5-fluoro-1l-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine [(-)-FTC)], a substituted oxathiolane compound with anti-hepatitis B virus activity in vitro, was assessed for its efficacy in woodchucks with naturally acquired woodchuck hepatitis virus (WHV) infection. Pharmacokinetics and in vitro anabolism were also determined. (-)-FTC was anabolized to the 5'-triphosphate in a dose-related fashion, reaching a maximum concentration at about 24 h in cultured woodchuck hepatocytes. Following administration of a dose of 10 mg/kg of body weight intraperitoneally (i.p.), the clearance of (-)-FTC from plasma was monoexponential, the terminal half-life was 3.76 +/- 1.4 h, and the systemic clearance was 0.12 +/- 0.06 liters/h/kg. The antiviral efficacy of (-)-FTC in the woodchuck model was assessed by quantitation of serum WHV DNA levels and by WHV particle-associated DNA polymerase activity at two dosages, 30 and 20 mg/kg given i.p. twice daily (b.i.d.), respectively. The level of WHV DNA in serum was reduced 20- to 150-fold (average, 56-fold) in the 30-mg/kg-b.i.d. treatment group and 6- to 49-fold (average, 27-fold) in the 20-mg/kg-b.i.d. treatment group. Viral DNA polymerase levels diminished accordingly. One week after treatment was discontinued, WHV levels returned to pretreatment levels in both studies. These animals were biopsied before and following treatment with 30 mg of (-)-FTC per kg. Their livers were characterized by a mild increase in cytoplasmic lipid levels, but this change was not associated with altered liver enzyme levels. Serum chemistry and hematology results were within the normal ranges for all treated animals. We conclude that (-)-FTC is a potent antihepadnaviral agent and that it has no detectable toxic effects in woodchucks when given for up to 25 days. Further development of (-)-FTC as an anti-hepatitis B virus therapy for patients is warranted.

Full Text

The Full Text of this article is available as a PDF (235.6 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bartholomew M. M., Jansen R. W., Jeffers L. J., Reddy K. R., Johnson L. C., Bunzendahl H., Condreay L. D., Tzakis A. G., Schiff E. R., Brown N. A. Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet. 1997 Jan 4;349(9044):20–22. doi: 10.1016/S0140-6736(96)02266-0. [DOI] [PubMed] [Google Scholar]
  2. Bassendine M. F., Chadwick R. G., Salmeron J., Shipton U., Thomas H. C., Sherlock S. Adenine arabinoside therapy in HBsAg-positive chronic liver disease: a controlled study. Gastroenterology. 1981 May;80(5 Pt 1):1016–1022. [PubMed] [Google Scholar]
  3. Beasley R. P., Hwang L. Y., Lin C. C., Chien C. S. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan. Lancet. 1981 Nov 21;2(8256):1129–1133. doi: 10.1016/s0140-6736(81)90585-7. [DOI] [PubMed] [Google Scholar]
  4. Carreño V., Porres J. C., Mora I., Gutiez J., Quiroga J. A., Ramón y Cajal S., Oliva H., Compernolle C., Bartolomé J. A controlled study of treatment with recombinant interferon alpha in chronic hepatitis B virus infection: induction and maintenance schedules. Antiviral Res. 1987 Oct;8(3):125–137. doi: 10.1016/0166-3542(87)90066-0. [DOI] [PubMed] [Google Scholar]
  5. Condreay L. D., Jansen R. W., Powdrill T. F., Johnson L. C., Selleseth D. W., Paff M. T., Daluge S. M., Painter G. R., Furman P. A., Ellis M. N. Evaluation of the potent anti-hepatitis B virus agent (-) cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine in a novel in vivo model. Antimicrob Agents Chemother. 1994 Mar;38(3):616–619. doi: 10.1128/aac.38.3.616. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Cote P. J., Engle R. E., Langer C. A., Ponzetto A., Gerin J. L. Antigenic analysis of woodchuck hepatitis virus surface antigen with site-specific radioimmunoassays. J Virol. 1984 Mar;49(3):701–708. doi: 10.1128/jvi.49.3.701-708.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Cullen J. M., Marion P. L., Newbold J. E. A sequential histologic and immunohistochemical study of duck hepatitis B virus infection in Pekin ducks. Vet Pathol. 1989 Mar;26(2):164–172. doi: 10.1177/030098588902600210. [DOI] [PubMed] [Google Scholar]
  8. Cullen J. M., Marion P. L. Non-neoplastic liver disease associated with chronic ground squirrel hepatitis virus infection. Hepatology. 1996 Jun;23(6):1324–1329. doi: 10.1002/hep.510230605. [DOI] [PubMed] [Google Scholar]
  9. Davis M. G., Wilson J. E., VanDraanen N. A., Miller W. H., Freeman G. A., Daluge S. M., Boyd F. L., Aulabaugh A. E., Painter G. R., Boone L. R. DNA polymerase activity of hepatitis B virus particles: differential inhibition by L-enantiomers of nucleotide analogs. Antiviral Res. 1996 May;30(2-3):133–145. doi: 10.1016/0166-3542(96)00938-2. [DOI] [PubMed] [Google Scholar]
  10. Doong S. L., Tsai C. H., Schinazi R. F., Liotta D. C., Cheng Y. C. Inhibition of the replication of hepatitis B virus in vitro by 2',3'-dideoxy-3'-thiacytidine and related analogues. Proc Natl Acad Sci U S A. 1991 Oct 1;88(19):8495–8499. doi: 10.1073/pnas.88.19.8495. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Fourel I., Cullen J. M., Saputelli J., Aldrich C. E., Schaffer P., Averett D. R., Pugh J., Mason W. S. Evidence that hepatocyte turnover is required for rapid clearance of duck hepatitis B virus during antiviral therapy of chronically infected ducks. J Virol. 1994 Dec;68(12):8321–8330. doi: 10.1128/jvi.68.12.8321-8330.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Fourel I., Hantz O., Cova L., Allaudeen H. S., Trepo C. Main properties of duck hepatitis B virus DNA polymerase: comparison with the human and woodchuck hepatitis B virus DNA polymerases. Antiviral Res. 1987 Nov;8(4):189–199. doi: 10.1016/0166-3542(87)90073-8. [DOI] [PubMed] [Google Scholar]
  13. Fourel I., Hantz O., Watanabe K. A., Jacquet C., Chomel B., Fox J. J., Trepo C. Inhibitory effects of 2'-fluorinated arabinosyl-pyrimidine nucleosides on woodchuck hepatitis virus replication in chronically infected woodchucks. Antimicrob Agents Chemother. 1990 Mar;34(3):473–475. doi: 10.1128/aac.34.3.473. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Frick L. W., St John L., Taylor L. C., Painter G. R., Furman P. A., Liotta D. C., Furfine E. S., Nelson D. J. Pharmacokinetics, oral bioavailability, and metabolic disposition in rats of (-)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl] cytosine, a nucleoside analog active against human immunodeficiency virus and hepatitis B virus. Antimicrob Agents Chemother. 1993 Nov;37(11):2285–2292. doi: 10.1128/aac.37.11.2285. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Furman P. A., Davis M., Liotta D. C., Paff M., Frick L. W., Nelson D. J., Dornsife R. E., Wurster J. A., Wilson L. J., Fyfe J. A. The anti-hepatitis B virus activities, cytotoxicities, and anabolic profiles of the (-) and (+) enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine. Antimicrob Agents Chemother. 1992 Dec;36(12):2686–2692. doi: 10.1128/aac.36.12.2686. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Galibert F., Chen T. N., Mandart E. Nucleotide sequence of a cloned woodchuck hepatitis virus genome: comparison with the hepatitis B virus sequence. J Virol. 1982 Jan;41(1):51–65. doi: 10.1128/jvi.41.1.51-65.1982. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Gerin J. L., Korba B. E., Cote P. J., Tennant B. C. A preliminary report of a controlled study of thymosin alpha-1 in the woodchuck model of hepadnavirus infection. Adv Exp Med Biol. 1992;312:121–123. doi: 10.1007/978-1-4615-3462-4_11. [DOI] [PubMed] [Google Scholar]
  18. Gust I. D., Burrell C. J., Coulepis A. G., Robinson W. S., Zuckerman A. J. Taxonomic classification of human hepatitis B virus. Intervirology. 1986;25(1):14–29. doi: 10.1159/000149651. [DOI] [PubMed] [Google Scholar]
  19. Habteyesus A., Nordenskjöld A., Bohman C., Eriksson S. Deoxynucleoside phosphorylating enzymes in monkey and human tissues show great similarities, while mouse deoxycytidine kinase has a different substrate specificity. Biochem Pharmacol. 1991 Oct 9;42(9):1829–1836. doi: 10.1016/0006-2952(91)90522-7. [DOI] [PubMed] [Google Scholar]
  20. Hantz O., Allaudeen H. S., Ooka T., De Clercq E., Trepo C. Inhibition of human and woodchuck hepatitis virus DNA polymerase by the triphosphates of acyclovir, 1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)-5-iodocytosine and E-5-(2-bromovinyl)-2'-deoxyuridine. Antiviral Res. 1984 Aug;4(4):187–199. doi: 10.1016/0166-3542(84)90017-2. [DOI] [PubMed] [Google Scholar]
  21. Hantz O., Ooka T., Vitvitski L., Pichoud C., Trepo C. Comparison of properties of woodchuck hepatitis virus and human hepatitis B virus endogenous DNA polymerases. Antimicrob Agents Chemother. 1984 Feb;25(2):242–246. doi: 10.1128/aac.25.2.242. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Kaplan P. M., Greenman R. L., Gerin J. L., Purcell R. H., Robinson W. S. DNA polymerase associated with human hepatitis B antigen. J Virol. 1973 Nov;12(5):995–1005. doi: 10.1128/jvi.12.5.995-1005.1973. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Kassianides C., Hoofnagle J. H., Miller R. H., Doo E., Ford H., Broder S., Mitsuya H. Inhibition of duck hepatitis B virus replication by 2',3'-dideoxycytidine. A potent inhibitor of reverse transcriptase. Gastroenterology. 1989 Nov;97(5):1275–1280. doi: 10.1016/0016-5085(89)91699-5. [DOI] [PubMed] [Google Scholar]
  24. Korba B. E., Wells F., Tennant B. C., Cote P. J., Gerin J. L. Lymphoid cells in the spleens of woodchuck hepatitis virus-infected woodchucks are a site of active viral replication. J Virol. 1987 May;61(5):1318–1324. doi: 10.1128/jvi.61.5.1318-1324.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Korba B. E., Wells F., Tennant B. C., Yoakum G. H., Purcell R. H., Gerin J. L. Hepadnavirus infection of peripheral blood lymphocytes in vivo: woodchuck and chimpanzee models of viral hepatitis. J Virol. 1986 Apr;58(1):1–8. doi: 10.1128/jvi.58.1.1-8.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Löfgren B., Nordenfelt E., Oberg B. Inhibition of RNA- and DNA-dependent duck hepatitis B virus DNA polymerase activity by nucleoside and pyrophosphate analogs. Antiviral Res. 1989 Dec;12(5-6):301–310. doi: 10.1016/0166-3542(89)90057-0. [DOI] [PubMed] [Google Scholar]
  27. Mason W. S., Cullen J., Saputelli J., Wu T. T., Liu C., London W. T., Lustbader E., Schaffer P., O'Connell A. P., Fourel I. Characterization of the antiviral effects of 2' carbodeoxyguanosine in ducks chronically infected with duck hepatitis B virus. Hepatology. 1994 Feb;19(2):398–411. [PubMed] [Google Scholar]
  28. Mason W. S., Taylor J. M. Experimental systems for the study of hepadnavirus and hepatitis delta virus infections. Hepatology. 1989 Apr;9(4):635–645. doi: 10.1002/hep.1840090420. [DOI] [PubMed] [Google Scholar]
  29. McKenzie R., Fried M. W., Sallie R., Conjeevaram H., Di Bisceglie A. M., Park Y., Savarese B., Kleiner D., Tsokos M., Luciano C. Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B. N Engl J Med. 1995 Oct 26;333(17):1099–1105. doi: 10.1056/NEJM199510263331702. [DOI] [PubMed] [Google Scholar]
  30. Paff M. T., Averett D. R., Prus K. L., Miller W. H., Nelson D. J. Intracellular metabolism of (-)- and (+)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine in HepG2 derivative 2.2.15 (subclone P5A) cells. Antimicrob Agents Chemother. 1994 Jun;38(6):1230–1238. doi: 10.1128/aac.38.6.1230. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Perrillo R. P., Schiff E. R., Davis G. L., Bodenheimer H. C., Jr, Lindsay K., Payne J., Dienstag J. L., O'Brien C., Tamburro C., Jacobson I. M. A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group. N Engl J Med. 1990 Aug 2;323(5):295–301. doi: 10.1056/NEJM199008023230503. [DOI] [PubMed] [Google Scholar]
  32. Ponzetto A., Cote P. J., Ford E. C., Purcell R. H., Gerin J. L. Core antigen and antibody in woodchucks after infection with woodchuck hepatitis virus. J Virol. 1984 Oct;52(1):70–76. doi: 10.1128/jvi.52.1.70-76.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Popper H., Roth L., Purcell R. H., Tennant B. C., Gerin J. L. Hepatocarcinogenicity of the woodchuck hepatitis virus. Proc Natl Acad Sci U S A. 1987 Feb;84(3):866–870. doi: 10.1073/pnas.84.3.866. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Rajagopalan P., Boudinot F. D., Chu C. K., Tennant B. C., Baldwin B. H., Schinazi R. F. Pharmacokinetics of (-)-2'-3'-dideoxy-3'-thiacytidine in woodchucks. Antimicrob Agents Chemother. 1996 Mar;40(3):642–645. doi: 10.1128/aac.40.3.642. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Renault P. F., Hoofnagle J. H. Side effects of alpha interferon. Semin Liver Dis. 1989 Nov;9(4):273–277. doi: 10.1055/s-2008-1040523. [DOI] [PubMed] [Google Scholar]
  36. Roggendorf M., Tolle T. K. The woodchuck: an animal model for hepatitis B virus infection in man. Intervirology. 1995;38(1-2):100–112. doi: 10.1159/000150418. [DOI] [PubMed] [Google Scholar]
  37. Roth L., King J. M., Hornbuckle W. E., Harvey H. J., Tennant B. C. Chronic hepatitis and hepatocellular carcinoma associated with persistent woodchuck hepatitis virus infection. Vet Pathol. 1985 Jul;22(4):338–343. doi: 10.1177/030098588502200407. [DOI] [PubMed] [Google Scholar]
  38. Schalm S. W., Thomas H. C., Hadziyannis S. J. Chronic hepatitis B. Prog Liver Dis. 1990;9:443–462. [PubMed] [Google Scholar]
  39. Schinazi R. F., Lloyd R. M., Jr, Nguyen M. H., Cannon D. L., McMillan A., Ilksoy N., Chu C. K., Liotta D. C., Bazmi H. Z., Mellors J. W. Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides. Antimicrob Agents Chemother. 1993 Apr;37(4):875–881. doi: 10.1128/aac.37.4.875. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Schinazi R. F., McMillan A., Cannon D., Mathis R., Lloyd R. M., Peck A., Sommadossi J. P., St Clair M., Wilson J., Furman P. A. Selective inhibition of human immunodeficiency viruses by racemates and enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine. Antimicrob Agents Chemother. 1992 Nov;36(11):2423–2431. doi: 10.1128/aac.36.11.2423. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Scullard G. H., Andres L. L., Greenberg H. B., Smith J. L., Sawhney V. K., Neal E. A., Mahal A. S., Popper H., Merigan T. C., Robinson W. S. Antiviral treatment of chronic hepatitis B virus infection: improvement in liver disease with interferon and adenine arabinoside. Hepatology. 1981 May-Jun;1(3):228–232. doi: 10.1002/hep.1840010306. [DOI] [PubMed] [Google Scholar]
  42. Shaw T., Amor P., Civitico G., Boyd M., Locarnini S. In vitro antiviral activity of penciclovir, a novel purine nucleoside, against duck hepatitis B virus. Antimicrob Agents Chemother. 1994 Apr;38(4):719–723. doi: 10.1128/aac.38.4.719. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Sherker A. H., Hirota K., Omata M., Okuda K. Foscarnet decreases serum and liver duck hepatitis B virus DNA in chronically infected ducks. Gastroenterology. 1986 Oct;91(4):818–824. doi: 10.1016/0016-5085(86)90681-5. [DOI] [PubMed] [Google Scholar]
  44. Smee D. F., Knight S. S., Duke A. E., Robinson W. S., Matthews T. R., Marion P. L. Activities of arabinosyladenine monophosphate and 9-(1,3-dihydroxy-2-propoxymethyl)guanine against ground squirrel hepatitis virus in vivo as determined by reduction in serum virion-associated DNA polymerase. Antimicrob Agents Chemother. 1985 Feb;27(2):277–279. doi: 10.1128/aac.27.2.277. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Staschke K. A., Colacino J. M., Mabry T. E., Jones C. D. The in vitro anti-hepatitis B virus activity of FIAU [1-(2'-deoxy-2'-fluoro-1-beta-D-arabinofuranosyl-5-iodo)uracil] is selective, reversible, and determined, at least in part, by the host cell. Antiviral Res. 1994 Jan;23(1):45–61. doi: 10.1016/0166-3542(94)90032-9. [DOI] [PubMed] [Google Scholar]
  46. Suzuki S., Lee B., Luo W., Tovell D., Robins M. J., Tyrrell D. L. Inhibition of duck hepatitis B virus replication by purine 2',3'-dideoxynucleosides. Biochem Biophys Res Commun. 1988 Nov 15;156(3):1144–1151. doi: 10.1016/s0006-291x(88)80752-6. [DOI] [PubMed] [Google Scholar]
  47. Tencza M. G., Newbold J. E. Heterogeneous response for a mammalian hepadnavirus infection to acyclovir: drug-arrested intermediates of minus-strand viral DNA synthesis are enveloped and secreted from infected cells as virion-like particles. J Med Virol. 1997 Jan;51(1):6–16. [PubMed] [Google Scholar]
  48. Tencza M. G., Newbold J. E. Heterogeneous response for a mammalian hepadnavirus infection to acyclovir: drug-arrested intermediates of minus-strand viral DNA synthesis are enveloped and secreted from infected cells as virion-like particles. J Med Virol. 1997 Jan;51(1):6–16. [PubMed] [Google Scholar]
  49. Tisdale M., Kemp S. D., Parry N. R., Larder B. A. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc Natl Acad Sci U S A. 1993 Jun 15;90(12):5653–5656. doi: 10.1073/pnas.90.12.5653. [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Venkateswaran P. S., Millman I., Blumberg B. S. Effects of an extract from Phyllanthus niruri on hepatitis B and woodchuck hepatitis viruses: in vitro and in vivo studies. Proc Natl Acad Sci U S A. 1987 Jan;84(1):274–278. doi: 10.1073/pnas.84.1.274. [DOI] [PMC free article] [PubMed] [Google Scholar]
  51. Weissberg J. I., Andres L. L., Smith C. I., Weick S., Nichols J. E., Garcia G., Robinson W. S., Merigan T. C., Gregory P. B. Survival in chronic hepatitis B. An analysis of 379 patients. Ann Intern Med. 1984 Nov;101(5):613–616. doi: 10.7326/0003-4819-101-5-613. [DOI] [PubMed] [Google Scholar]
  52. Yarchoan R., Perno C. F., Thomas R. V., Klecker R. W., Allain J. P., Wills R. J., McAtee N., Fischl M. A., Dubinsky R., McNeely M. C. Phase I studies of 2',3'-dideoxycytidine in severe human immunodeficiency virus infection as a single agent and alternating with zidovudine (AZT). Lancet. 1988 Jan 16;1(8577):76–81. doi: 10.1016/s0140-6736(88)90283-8. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES